Hematological profiles of goats naturally infected with Anaplasma ovis in north and northeast Iran

This study was conducted to measure selected hematological parameters in goats naturally infected with Anaplasma ovis. In this study 193 blood samples were collected from adult and young goats in north (Gonbad) and northeast (Mashhad) of Iran. Out of the 193 blood samples, 123 samples were positive (infected group) and 70 samples were negative (uninfected group) for A. ovis by polymerase chain reaction. Hematological analysis was carried out on 47 samples from the infected group and 37 samples from the uninfected group. Hematological analysis indicated significant decreases (P?<?0.01) in RBC counts, HCT values, and hemoglobin concentrations in the A. ovis-infected group of goats compared to the uninfected group (P?<?0.01). The mean corpuscular volume, mean corpuscular hemoglobin, WBC counts, lymphocytes, eosinophils, and monocytes in the infected group were lower but neutrophils were higher than in the uninfected group. These differences were not statistically significant (P?>?0.05). The result from this study revealed that A. ovis infection in goats is associated with marked changes in hematological parameters.     

Effects of acrylic resin monomers on porcine coronary artery reactivity

The purpose of the present investigation was to assess the reactivity of porcine coronary arteries under in vitro conditions following their exposure to methyl methacrylate (MMA) and hydroxyethyl methacrylate (HEMA) monomers. Confirming previous studies using rat aortas, both MMA and HEMA induced acute/direct relaxation of coronary ring preparations, which was partly dependent on the endothelium. With prolonged tissue exposure, both monomers caused time- and concentration-dependent inhibition of receptor-mediated contraction of the vascular smooth muscle caused by prostaglandin F_2∝ (PGF_2∝), with HEMA causing more inhibition than MMA. Hydroxyethyl methacrylate, but not MMA, also produced impairment of non-receptor-mediated contraction of the coronary smooth muscle induced by KCl. On the other hand, neither HEMA nor MMA altered relaxation of the smooth muscle produced by the direct-acting pharmacological agent, sodium nitroprusside (SNP). While exposure to HEMA impaired endothelium-dependent vasorelaxation caused by bradykinin (BK), MMA markedly enhanced this endothelial-mediated response of the arteries. The enhanced endothelial response produced by MMA was linked to nitric oxide (NO) release. In conclusion, with prolonged tissue exposure, MMA causes less pronounced effects/adverse consequences on coronary smooth muscle function relative to the effect of HEMA, while enhancing vasorelaxation associated with release of NO from the endothelium. Accordingly, MMA-containing resin materials appear to be safer for human applications than materials containing HEMA.     

Treatment of pediatric femoral shaft fractures with titanium elastic nails–our experience

Management of femoral diaphyseal fractures in the age group of 6-16 years is controversial. There has been a resurgence worldwide for operative fixation in general and TENS (titanium elastic nailing system) in particular.We performed a retrospective review of pediatric femoral fractures treated by TENS. The data was collected from cases operated between July 2007 and June 2010 at Sohar Hospital, Oman.We had treated 16 children (14 boys and 2 girls) with TENS for femoral shaft fractures. The mean age was 12.5 years (range 7-16 years) and mean hospital stay was 7.6 days (range 4-15 days). All fractures were radio-graphically united at a mean of 7.5 weeks (range 5-10 weeks). The nails were removed in 14 children after a mean of 22 weeks (range 6-38 weeks) postoperatively. At follow-up, we had found leg length discrepancy of 1 cm in one child and 10° of internal rotational deformity in another. No angular deformity had occurred.Titanium elastic nailing seems to be a safe and effective method for the treatment of femoral shaft fractures in children between 7 and 16 years of age.     

Efficacy of clofibrate on severe neonatal jaundice associated with glucose-6-phosphate dehydrogenase deficiency (a randomized clinical trial)

Glucose-6-phosphate dehydrogenase (G6PD) deficiency may cause severe hyperbilirubinemia with bilirubin encephalopathy unless intervention is initiated. The aim of this study was to assess the efficacy of clofibrate in full term G6PD deficient neonates with jaundice. A randomized clinical trial study was performed in two groups of full-term G6PD deficient jaundiced neonates (clofibrate treated group, n = 21; control group, n = 19). Infants in the clofibrate group received a single oral dose of 100 mg/kg clofibrate, whereas control group received nothing. Both groups were treated with phototherapy. Serum total and direct bilirubin levels were measured at the onset of treatments, 16, 24 and 48 hours later. On enrollment, the mean total serum bilirubin (TSB) level in the clofibrate treated group was 18.40 +/- 2.41 and in the control group was 17.49 +/- 1.03 (p = 0.401). At 16, 24 and 48 hours of treatment, the mean TSB in the clofibrate group were 15.2 +/- 1.9, 12.6 +/- 2.4, and 10.1 +/- 2.4 and in the control group were 16.5 +/- 1.2, 13.3 +/- 2.2 and 11.4 +/- 2.4, respectively (p = 0.047). At 48 hours, 7 (33%) cases in the clofibrate group and one (5%) case in the control group were discharged with a TSB < 10 mg/dl (p = 0.031). No side effects were observed on serial examinations during hospitalization, or on the 1st and 7th days after discharge. The results show that clofibrate induces a faster decline in serum total bilirubin level, a shorter duration of phototherapy, and hospitalization with no side effects in full-term G6PD deficient neonates with jaundice.